Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Mar;9(2):115-9.
doi: 10.1007/s11912-007-0007-2.

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

Guru Sonpavde  1 , Thomas E Hutson
Affiliations
Review

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

Guru Sonpavde et al. Curr Oncol Rep. 2007 Mar.

Abstract

Pazopanib (GW786034) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. Preclinical evaluation has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. Significant antitumor activity was found in animal models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies.

PubMed Disclaimer

References

    1. Cancer Res. 2004 Oct 1;64(19):7099-109 - PubMed
    1. Science. 1997 Jul 11;277(5323):242-5 - PubMed
    1. Nat Med. 1995 Feb;1(2):149-53 - PubMed
    1. J Clin Oncol. 2005 Feb 10;23 (5):1028-43 - PubMed
    1. Annu Rev Biochem. 2000;69:373-98 - PubMed

Publication types

LinkOut - more resources